Skip to main content

Growth factor enriched collagen matrix versus de-epithelialized graft in root coverage procedures - A randomized parallel arm clinical trial

In brief

Collagen matrix with platelet-rich fibrin matches graft for root coverage

In a single-blind trial of 45 patients with maxillary recession, a collagen matrix enriched with injectable platelet-rich fibrin achieved about 82% mean root coverage, statistically indistinguishable from the 90% seen with a de-epithelialized free gingival graft. Both techniques reduced recession depth similarly at 6 and 12 months, suggesting the matrix is a viable, less invasive alternative.

Journal
Journal of oral biology and craniofacial research (Q2)
Published
3 September 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Sanathana Polimera, Anupama Tadepalli, Harinath Parthasarathy, Priyanka K Cholan, Lakshmi Ramachandran
PMID
42733495
DOI
10.1016/j.jobcr.2026.101528

Why clinicians should know about it

  • Picked for Otorhinolaryngology (top studies of the week, 20 September 2026): Dental gingival recession, no ENT relevance

Abstract

AIM: This randomized parallel arm single blinded trial, evaluated the clinical efficacies of de epithelialized free gingival graft (DFGG) and volume stable collagen matrix (VCMX) enriched with injectable platelet-rich fibrin (i-PRF) along with coronally advanced flap (CAF) for the treatment of recession defects. The objectives were to assess and compare changes in recession depth (RD) and root coverage percentage (RC) between the groups. MATERIALS AND METHODS: Forty-five systemically healthy individuals presenting Cairo's RT1/RT2 recession defects in the maxilla were treated either with control (CAF + DFGG, n = 23) or test intervention (CAF + i-PRF + VCMX, n = 22). Parameters such as recession depth (RD) and keratinized tissue width (KTW) were measured at baseline, 6 and 12 months. Mean and complete root coverage percentages (MRC and CRC) were calculated. RESULTS: From baseline to 12 months, a statistically significant reduction in mean RD was observed in both the treatment groups (p < 0.001). At 12 months, the control group demonstrated a MRC of 90.21 ± 28.93% and CRC of 89.13 ± 29.99% and the test group showed a MRC of 81.62 ± 32.03% with CRC of 72.73 ± 45.58%. Intergroup analysis revealed no statistically significant differences in the measured clinical parameters at 6 and 12 months (p > 0.05). CONCLUSION: Within the limits of this study, volume-stable xenogeneic collagen matrix enriched with i-PRF resulted in similar outcomes to those achieved with de-epithelialized free gingival graft in the treatment of maxillary gingival recession defects.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.